Study on Impact of Fentanyl Matrix on Improvement of Pain and Functioning in Spinal Disorder-related Pain
CompletedNCT00797017
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of this observational study is to investigate the impact of fentanyl matrix on improvement of pain and functioning in spinal disorder-related chronic pain.
Study details
- Official title
- Impact of Fentanyl Matrix on Improvement of Pain and Functioning in Spinal Disorder-related Pain: Multicenter, Open Label, Prospective, Observational Study
- Conditions
- Interventions
- Sponsor
- Janssen Korea, Ltd., Korea
- Start date
- 2008-05
- Primary completion
- 2008-12
- Sex
- All
- Age range
- from 20 Years
- Results posted
- No results posted in this snapshot
- Total sites listed
- 0
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients who complain of spinal disorder-related chronic pain persisting for 3 months or longer * Patients who can fully observe the overall clinical study requirements including K-ODI completion at the investigator's discretion * Patients who complain of severe pain (NRS score = 7) because pain was not treated enough with the previous analgesic * Patients who have never been administered fentanyl matrix over the last one month Exclusion Criteria: * Patients with a history of the drug or alcohol abuse in the past or now * Childbearing women who are pregnant or likely to be pregnant during the study period and male patients who are neither infertile nor willing to refrain from sexual relations but whose partner does not conduct an effective contraception (implant, injections, oral contraceptives, intrauterine device, etc.) * Patients who are unable to use a transdermal system due to skin disease * Patients with serious mental disorder * Patients with history of hypersensitivity to opioid analgesics * Patients with history of CO2 retention * Patients who are not eligible for the study participation based on warnings, precautions and contra medications in the package insert of the study drug at the investigator's discretion
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00797017